卵巢癌组织SEMA3F表达及甲基化初步研究  

Expression and methyation of SEMA3F in epithelial ovarian tumors

作　　者：裴雪阳 徐云钊[1] 谭细娟 叶青[1] 奚庆华[1] 

机构地区：[1]南通大学附属医院妇产科,江苏南通226001

出　　处：《中华肿瘤防治杂志》2014年第20期1611-1616,共6页Chinese Journal of Cancer Prevention and Treatment

摘　　要：目的研究神经轴突导向分子SEMA3F在不同卵巢上皮肿瘤组织的表达及其与上皮性卵巢癌各临床病理参数及预后的关系,并初步探讨SEMA3F启动子区甲基化与上皮性卵巢癌的关系。方法选取2004-12-01-2008-12-30南通大学附属医院收集的95例卵巢癌、30例交界性卵巢上皮肿瘤、30例良性卵巢上皮肿瘤和10例正常卵巢组织标本,采用免疫组织化学方法检测SEMA3F的表达。应用半定量RT-PCR法检测2013-05-01-2013-12-31南通大学附属医院收集的12例新鲜上皮性卵巢癌、10例新鲜良性卵巢上皮肿瘤、10例新鲜正常卵巢组织中SEMA3F的表达水平,并通过亚硫酸氢盐测序法(BSP)检测上皮性卵巢癌中SEMA3F启动子区的甲基化情况,用SPSS 17.0统计软件分析数据。结果免疫组化显示,SEMA3F在不同卵巢上皮肿瘤组织中的表达水平不同,在上皮性卵巢癌组织中表达下降或缺失明显,结合临床资料分析显示,SEMA3F表达与上皮性卵巢癌的临床分期(χ2=27.100,P<0.001)、组织学分级(χ2=10.673,P=0.005)及有无盆腔外腹膜转移(z=-4.447,P<0.001)有关,但与患者的年龄(z=-0.670,P=0.503)、组织分类(χ2=3.729,P=0.444)和淋巴结转移(z=-0.584,P=0.559)无关。Kaplan-Meier分析显示,SEMA3F阴性或低表达组患者5年生存率为23.5%(16/68),明显低于SEMA3F高表达组的52.6%(10/19),差异有统计学意义,χ2=7.460,P=0.006。RT-PCR结果显示,SEMA3FmRNA相对表达量在正常卵巢组织(1±0.080)、良性卵巢上皮肿瘤(0.927±0.116)和上皮性卵巢癌中(0.436±0.122)依次下降,前两者表达差异无统计学意义,t=0.533,P>0.05,但正常卵巢与上皮性卵巢癌组织中SEMA3F的表达差异有统计学意义,t=3.820,P<0.05,且良性卵巢上皮肿瘤与上皮性卵巢癌组织中SEMA3F表达差异亦有统计学意义,t=2.979,P<0.05。上皮性卵巢癌和正常卵巢组织中SEMA3F启动子区的平均甲基化率分别为23.17%和20.00%,两者之间差异无统计学意义,t=0.890,P>0.05。结论SEOBJECTIVE To investigate the expression of SEMA3 Fin different human epithelial ovarian tumors and the correlation with the clinic pathologic stages as well as the prognosis of ovarian cancer patients,and study the effects of promoter methylation of SEMA3 Fon human epithelial ovarian cancer.METHODS The expression of SEMA3 Fwas investigated by immunohistochemical staining in 95 cases of epithelial ovarian cancer,30 cases of borderline ovarian epithelial tumors,and 30 cases of benign ovarian epithelial tumors as well as 10 normal ovarian tissues which were chosen from Affiliated Hospital of NanTong University during from 2004-12-01 to 2008-12-30.SEMA3 F mRNA expression was detected using RT-PCR in 12 cases of epithelial ovarian cancer,10 cases of benign ovarian epithelial tumors and 10 normal ovarian tissues also were chosen from Affiliated Hospital of NanTong University during from 2013-05-01 to 2013-12-31.The promoter methylation of SEMA3 Fwas observed by BSP.The data was analyzed with SPSS17.0statistical software.RESULTS Immunohistochemical analysis revealed that the expression of SEMA3 Fin ovarian cancer,borderline ovarian tumor,benign ovarian tumor and normal tissue were significantly different.The expression of SEMA3 Fsignificantly decreased in ovarian cancer,which even deleted in some cases.It was significantly associated with pathologic stages（χ2=27.100,P〈0.001）,histological grades（χ2=10.673,P=0.005）and whether presented beyond the pelvic peritoneal metastases or not（z=-4.447,P〈0.001）.There was no relation with the age of the patient（z=-0.670,P=0.503）,histological classification of the tumors（χ2=3.729,P=0.444）or lymph node metastasis（z=-0.584,P=0.559）.The Kaplan-Meier method test showed that the five year survival rate for patients with negative or low expression of SEMA3F（23.5%）was significantly lower than that with high expression（52.6%）which showed statistical difference,χ2=7.460,P=0.006.The relative mRNA expression level of SEMA3 Fin normal tissue（1±0.080）,be

关 键 词：卵巢肿瘤 SEMA3F 甲基化 诊断 预后 

分 类 号：R737.31[医药卫生—肿瘤]